Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings Of The Fortnight Finds Reasons For Biopharma Hope In Recent Venture Capital News

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus details on recent financings by Cleave Biosciences, Incline Therapeutics, DNAnexus and Zeltiq Aesthetics.

You may also be interested in...



START-UP's 2011 Life Science Venture Capital Survey: Device Investors Feel The Sting Of FDA, Economy And Reform

START-UP's first life science venture survey asked all VCs how they feel about the state of the industry. Medical device VCs' answers reveal feelings of being beaten down by the FDA and the recession, and general concerns about the sector's ability to generate returns. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."

START-UP's 2011 Life Science Venture Capital Survey: Biopharmaceutical Investors Let Some Sunshine In

In START-UP's first life science venture survey, biopharma investors have plenty to complain about -- and they do -- but their generally positive outlook stands in contrast to that of their peers focused on medtech. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."

The A-List: 2010's Trend-Shaping Series A Financings

Investments for start-ups seeking their first infusion of venture capital continues to be scarce as venture firms seek later-stage opportunities and liquidity to improve their own chances of raising new funds.

Topics

UsernamePublicRestriction

Register

PS072890

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel